Clinical trial
KENya Single-dose HPV-vaccine Efficacy - The KEN-SHE Study
NCT03675256 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- KENya Single-dose HPV-vaccine Efficacy - The KEN-SHE Study
- Lead sponsor
- Massachusetts General Hospital
- Phase
- Phase 4
- Overall status
- Unknown status
- Start date
- December 19, 2018
- Completion date
- February 15, 2024
- Enrollment
- 2,275 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.